View
1.291
Download
0
Category
Preview:
DESCRIPTION
EUPATI Launch Meeting, 27 March 2012 - Jan Geissler
Citation preview
The European Patients’ Academy on Therapeutic Innovation
Jan GeisslerEUPATI Director, Germany
Window of opportunity in accelerating medicines R&D
Great challenges ahead: Personalized medicine, translational medicine, increasing development cost, pressure on healthcare budgets
The regulatory and innovation environment is ready to involve patients to effectively meet unmet needs
Patients…• seek up-to-date, credible, understandable information
about innovation in treatments• are largely unaware about clinical trials, translational
research, personalized medicine, pharmacoeconomics, their key role
Patient advocates…• like to advise on protocol design, informed consent,
ethical review, marketing authorization, value assessment, health policy
• lack the education and training required to participate as a partner in drug research and development
FP7-funded PatientPartner project demonstrateda clear need & willingness to contribute
Unmet need of patient & public, great willingness to contribute!
Launched Feb 2012, runs for 5 years,29 consortium members,IMI-funded
will develop and disseminateobjective, credible, correct and up-to-date public knowledge about medicinesR&D
A paradigm shift in empoweringpatients on medicines R&D
IMI-funded EUPATI will develop and disseminate accessible, well-structured and
user-friendly information and education on medicines R&D
build competencies among well informed patients and the public about pharmaceutical R&D
build expert capacity in patient advocates
create the leading public library on patient information in seven most common languages under public licensing
establish a widely used, sustainable infrastructure for objective, credible, correct and up-to-date knowledge
facilitate patient involvement in R&D to support industry, academia, authorities and ethics committees
EUPATI: European Patients' Academy on Therapeutic Innovation
Led by pan-EU patient umbrella organisations
Strong impetus from key academic partners and non-profit organisations
Key industry expertise in medicines R&D
Strong Consortium
Advisory bodies committed to ensure independence, transparency, good governance• EMA, Swissmedic, MHRA, BfArM• Key experts in bioethics, genetics, HTA,
economics, evidence based med, patient advocacy
• Ethics Panel Ethical Framework, Code of Conduct:
• Ground rules for anonymity, confidentiality, informed consent, social research, ethical review, professional integrity, publication ethics, transparency, independence and trust.
Ensuring Objectivity, Transparencyand Independence are vital
EUPATI platform fully loaded with training, education, information material in multiple languages
EUPATI Patient Ambassador, Patient Journalist, Train-the-Trainer Programme in place
Good practice guideline for patient involvement released
Annual Conferences and at least 5 Regional Workshops performed. Expert network established.
EUPATI in 2016: What we will have achieved
Get to know us!
Web:www.patientsacademy.eu
Twitter: @eupatientsas well as:
Recommended